ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 42 | November 1, 1985

Download PDF Visit The Full Archive

Related Articles

In Brief: O’Conor Names NCI Liaison To IARC, Saunders Acting IA Director Susan Sieber DCCP Deputy

May 27, 1983

DeVita Reshuffling NCI Office Space

April 18, 1980

Cancer Groups Fear Clinical Trials Coverage Will Not Be Implemented Across Exchanges

July 3, 2013

FDA Authority To Remove Paclitaxel Patent Questioned.

February 9, 2001

House Committee Investigates FDA Commissioner; False and Misleading Testimony Alleged.

April 6, 2007

In Brief: Carnegie Mellon President Emeritus honored By UPCI; Schiffer Leaves Maryland for Detroit

October 17, 1997